Reference (author, year) | Region | Definition of CSU in weeks | Number of CSU patients undergoing testing | Number of healthy controls undergoing testing | % prevalence of anti-TPO antibody in study group | % prevalence of anti-TPO antibody in control group | Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days |
---|---|---|---|---|---|---|---|
Verneuil, 2004 [103] | France | – | 45 | 30 | 17.8 | 3.3 | Not stated |
Gangemi, 2009 [104] | Italy | > 6 | 95 | 0 | 26.3 | – | Not stated |
Nuzzo, 2011 [105] | Italy | > 6 | 54 | 108 | 22.2 | 1.9 | Not allowed |
Alpay, 2013 [106] | Turkey | > 6 | 50 | 50 | 12 | 4 | 3 (AH) |
Cho, 2013 [107] | United States | > 6 | 27 | 20 | 11.1 | 20.0 | Not stated |
Wan, 2013 [108] | Taiwan | > 6 | 60 | 40 | 8.3 | 0 | Allowed (AH) |
Yadav, 2013 [109] | India | > 6 | 80 | 0 | 17.5 | – | 3 (AH), 21 (SC) |
Kim, 2016 [110] | Korea | > 6 | 184 | 0 | 13.6 | – | Not stated |
Czarnecka-Operacz, 2017 [111] | Poland | > 6 | 145 | 35 | 15.9 | – | Not stated |
Kasumagic-Halilovic, 2017 [112] | Bosnia and Herzegovina | > 6 | 70 | 70 | 30 | 1.4 | Not stated |
Schoepke, 2019 [98] | Multinational | > 6 | 182 | 0 | 20.9 | – | 3 (AH), 28 (SC) |